$AMRN Company News Expedia falls on Google penalty;

New Post Public Reply Private Reply Replies (0) Message Board

Jun 4, 2014 at 5:28 PM

$AMRN Company News

Expedia falls on Google penalty; Alcoa jumps on upgrade 4:54 p.m. Jan. 21, 2014 - Sue Chang
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 5:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Intercept, Celgene on move amid J.P. Morgan event 10:20 a.m. Jan. 13, 2014 - Victor Reklaitis
6 gut checks before the stock market's opening bell 7:12 a.m. July 8, 2013 - Shawn Langlois
6 gut checks before the stock market's opening bell 7:55 a.m. March 27, 2013 - Shawn Langlois
7 gut checks before the stock market's opening bell 8:05 a.m. Feb. 27, 2013 - Shawn Langlois
Friday’s big movers: Groupon soars on Google talk 5:38 p.m. Dec. 7, 2012 - Sue Chang
Amarin down 17% on risks tied to drug launch 9:00 a.m. Dec. 7, 2012 - Steve Gelsi
Amarin down 18% in premarket trades 8:41 a.m. Dec. 7, 2012 - Steve Gelsi
Wednesday’s biggest gaining and declining stocks 4:40 p.m. Oct. 10, 2012 - Sue Chang
Tuesday’s top gaining and declining stocks 4:57 p.m. Sept. 11, 2012 - MarketWatch
Amarin issues patent update on fish-oil drug 12:29 p.m. Sept. 5, 2012 - Val Brickates Kennedy
Amarin jumps 16% after business update 12:06 p.m. Aug. 9, 2012 - Val Brickates Kennedy
Amarin rallies 15% on business update 10:48 a.m. Aug. 9, 2012 - Val Brickates Kennedy
Amarin falls 11% on insider stock-sale reports 12:12 p.m. July 31, 2012 - Val Brickates Kennedy
Amarin, AuthenTec active; advancers outpace decliners 4-1 on NYSE 12:45 p.m. July 27, 2012 - blogs.marketwatch.com
Amarin down 9% in wake of drug approval 10:08 a.m. July 27, 2012 - Val Brickates Kennedy
Amarin gets FDA approval for Vascepa 6:09 p.m. July 26, 2012 - Wallace Witkowski
Amarin: FDA OKs Vascepa for high triglycerides 5:46 p.m. July 26, 2012 - Wallace Witkowski
Amarin halted ahead of FDA decision deadline 3:13 p.m. July 26, 2012 - Val Brickates Kennedy

Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows 10:09 a.m. May 23, 2014 - GuruFocus.com
Ligand-AstraZeneca Collaborate - Analyst Blog 6:00 p.m. May 19, 2014 - Zacks.com
Why Amarin (AMRN) Stock Is Plummeting Today 2:37 p.m. May 15, 2014 - TheStreet.com
Certain Amarin debt holders get a sweetener 12:53 p.m. May 15, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Amarin, Boeing, Cisco, KKR, NetApp, Twitter and More 8:02 a.m. May 12, 2014 - 247WallSt.com
Amarin's (AMRN) CEO John Thero on Q1 2014 Results - Earnings Call Transcript 12:20 p.m. May 9, 2014 - Seeking Alpha
More on Amarin Q1 results 7:37 a.m. May 9, 2014 - Seeking Alpha
10-Q: AMARIN CORP PLC\UK 7:11 a.m. May 9, 2014 - Edgar Online - (EDG = 10Q, 10K)
Move over Vascepa, here comes Epanova 7:08 a.m. May 6, 2014 - Seeking Alpha
Amarin Takes Step 1, Of A Million, To Right Its Ship 3:21 p.m. April 1, 2014 - Seeking Alpha
Amarin: How The Co-Promotion Agreement With Kowa Affects Required Sales Targets 12:53 a.m. April 1, 2014 - Seeking Alpha
Amarin +4.4% AH on U.S. Vascepa co-promotion deal 5:03 p.m. March 31, 2014 - Seeking Alpha
Looking For Value Among Biotechs After Precipitous Declines In Stock Price 12:26 p.m. March 24, 2014 - Seeking Alpha
Are Biotech Stocks Located in Ireland Top Buyout Candidates? 9:35 a.m. March 19, 2014 - 247WallSt.com
Amarin Management Discusses Q4 2013 Results - Earnings Call Transcript 11:20 p.m. Feb. 27, 2014 - Seeking Alpha
10-K: AMARIN CORP PLC\UK 5:15 p.m. Feb. 27, 2014 - Edgar Online - (EDG = 10Q, 10K)
Notable earnings after Thursday’s close 6:35 p.m. Feb. 26, 2014 - Seeking Alpha
Amarin Is Likely Now A Vortex Where Your Money Will Go To Die 3:16 p.m. Feb. 26, 2014 - Seeking Alpha
What Now For Amarin? 3:54 p.m. Feb. 25, 2014 - Seeking Alpha
Amarin's Vascepa Gets 3-Year Exclusivity - Analyst Blog 6:20 p.m. Feb. 24, 2014 - Zacks.com

Amarin to Present at the Jefferies 2014 Global Healthcare Conference 8:03 a.m. May 29, 2014 - Marketwire
Technical Pulse on Active Equities -- Research on Amarin, Abbott Laboratories, Apple, and T-MobileUS 10:23 a.m. May 16, 2014 - PR Newswire - PRF
Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes 5:00 a.m. May 15, 2014 - GlobeNewswire
Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations 7:01 a.m. May 9, 2014 - GlobeNewswire
Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014 8:01 a.m. May 5, 2014 - GlobeNewswire
Amarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels 8:02 a.m. May 2, 2014 - GlobeNewswire
Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical 2:10 p.m. April 25, 2014 - PR Newswire - PRF
Amarin Corp. and Kowa Pharmaceuticals to Begin Joint Vascepa Promotion in May 12:25 p.m. April 11, 2014 - ACCESSWIRE
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules 4:37 p.m. March 31, 2014 - GlobeNewswire
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health 12:19 p.m. March 28, 2014 - PR Newswire - PRF
Amarin Corporation plc. Analyst Report: Special Situation \ Turnaround Opportunity in Biopharmaceuticals - Targeting large existing cardiovascular health market by BrokerBank Securities, Inc. 7:00 a.m. March 28, 2014 - PR Newswire - PRF
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations 5:14 p.m. Feb. 27, 2014 - GlobeNewswire
Omega-3 Polyunsaturated Fatty Acids (PUFAs) - A Global Market Overview 2:59 p.m. Feb. 24, 2014 - PR Newswire - PRF
Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014 7:00 a.m. Feb. 24, 2014 - GlobeNewswire
Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules 5:01 p.m. Feb. 21, 2014 - GlobeNewswire
Amarin to Present at the 2014 Leerink Global Healthcare Conference 7:30 a.m. Feb. 6, 2014 - GlobeNewswire
Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales 7:00 a.m. Feb. 4, 2014 - GlobeNewswire
Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request 2:00 a.m. Jan. 21, 2014 - GlobeNewswire
Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement Request Will Be Delayed 5:05 p.m. Jan. 15, 2014 - GlobeNewswire
Equity Technical Dimensions:Seattle Genetics, Amarin, and PerkinElmer 9:00 a.m. Dec. 27, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...